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Three-dimensional (3D) engineered tissue constructs are a novel and promising approach to tissue repair and regeneration. 3D
tissue constructs have the ability to restore form and function to damaged soft tissue unlike previous methods, such as plastic
surgery, which are able to restore only form, leaving the function of the soft tissue often compromised. In this study, we seeded
murinemyoblasts(C2C12)intoacollagencompositescaﬀoldandculturedthescaﬀoldinarollerbottlecellculturesysteminorder
to create a 3D tissue graft in vitro. The 3D graft created in vitro was then utilized to investigate muscle tissue repair in vivo.T h e
3D muscle grafts were implanted into defect sites created in the skeletal muscles in mice. We detected that the scaﬀolds degraded
slowly over time, and muscle healing was improved which was shown by an increased quantity of innervated and vascularized
regenerated muscle ﬁbers. Our results suggest that the collagen composite scaﬀold seeded with myoblasts can create a 3D muscle
graft in vitro that can be employed for defect muscle tissue repair in vivo.
1.Introduction
Tissue loss usually results in signiﬁcant dysfunction, physical
deformities, and emotional pain long after treatment. Com-
mon causes of tissue loss include military injuries, such as
high-velocity missiles, fragmenting exploding devices, and
penetrating wounds associated with gunshots, and civilian
injuries, such as blunt trauma attributed to automobile
accidents [1]. Other causes of soft tissue removal include
tumor removal, diabetic tissue damage, and irradiative
injuries[2–5].Currenttreatmentsofsofttissueinjuries,such
as skeletal muscle defects, resort to reconstructive plastic
surgery, and skin grafting which are eﬀective techniques to
be employed in emergency repair and cosmetic applications,
but often these techniques are unable to provide restoration
of the function to the damaged tissue [6, 7].
Recent advances in biotechnology and bioengineering
have oﬀered novel approaches to repairing soft tissue defects
by combining cell biology, gene transfer, biomaterials, and
bioreactors [8–12]. Among the new advances, three-dimen-
sional biodegradable scaﬀolds provide the ability to restore
form and also function to the injured area. In order to be
successful, the 3D biodegradable scaﬀold needs to serve two
purposes. First, the scaﬀold needs to have the physiologic
and mechanical properties that mimic the in vivo native
environment, and second, the scaﬀold needs to have the
ability to allow for development and remodeling of the tissue
in order to promote successful restoration of physiological
function [13–15]. It is important for the scaﬀold to be
biodegradable because nondegradable constructs implanted
for prolonged time periods often induce an inﬂammatory
response which can often compromise the tissue construct
and the healing of the tissue [16–18].
Tissue and organ function are dependent on the presence
of appropriate populations of diﬀerentiated cells, and there-
fore, it is important to incorporate proper cells in the 3D
scaﬀold. This can be accomplished through rolling bottle cell
culture systems which are advantageous, in comparison to2 Journal of Biomedicine and Biotechnology
static cell seeding, in that a rolling bottle cell culture system
improves cell seeding density and homogeneity within the
scaﬀold [10, 19, 20]. This is accomplished through the slow
revolutions of the culture bottles on the rolling device which
produceaforcesigniﬁcantenoughtopermitthecellstogrow
evenly in three dimensions [21]. Also the revolutions allow
fornutrientstobeprovidedtothecellswhileatthesametime
removing waste products through the constant movement of
media bathing the cells [22].
In general, the artiﬁcial 3D scaﬀo l dp r o v i d e sa na r c h i -
tecture on which seeded cells can organize and develop into
the desired tissue for implantation. Once implanted in the
soft tissue defect, the biodegradable scaﬀold provides an
initial biomechanical structure for the replacement tissue
until the cells produce an adequate extracellular matrix.
During the deposition, organization, and formation of the
newly generated extracellular matrix, the scaﬀold is either
degraded or metabolized; eventually leaving a vital organ or
tissue that restores, maintains, or improves tissue function.
In this study, we built a 3D muscle graft by seeding C2C12
myoblasts into a biodegradable 3D collagen composite
scaﬀold,andimplanteditintoaskeletalmuscledefectmouse
model in vivo. Immunostaining was employed to evaluate
the eﬀectiveness of the graft in improving vascularization,
innervation, and regeneration of the damaged tissue.
2.MaterialsandMethods
2.1. C2C12 Myoblasts Transfected with Retroviral LacZ
and LacZ Staining. C2C12 myoblasts were purchased from
ATCC (American Type Culture Collection) and cultured in
media (DMEM, Invitrogen) supplemented with 10% fetal
bovine serum (FBS, Gibco, BR), 10% horse serum (HS),
1% penicillin/streptomycin (P/S), and 0.5% chick embryo
extract (CEE). The culture media was removed and replaced
with a 1:1 dilution of retroviral LacZ and culture media
supplemented with 8μg/mL of polybrene. The cells were
incubated in the solution for 6 hours at 5% CO2 and 37◦C.
To ensure maximum transduction of the virus, the infection
was done up to 3 times, and a LacZ staining was done after
each infection to determine the eﬃciency of the infections.
The LacZ staining consisted of ﬁxing the cells in 1%
glutaraldehyde solution (Sigma) for 2 minutes followed by
washing with PBS. The cells were then incubated for 2 hours
in a LacZ solution (225mL PBS/25mL KFE solution/250μL
of 2M MgCl2/5mL of X-gal) at 37◦C. The cells were then
visualized for analysis using bright ﬁeld microscopy.
2.2. 3D Collagen Composite Scaﬀold and Cell Seeding. The
3D collagen composite scaﬀolds were purchased from BD
Biosciences,(cataloguenumber354613)andthescaﬀoldsare
of a cylindrical shape approximately 4.2–5.2mm in diameter
and 3.9–4.5mm in height with a volume of 0.039cm3.
The average pore size of the scaﬀold is 100–200μm and the
hydration capacity is 25μL .Th ew e i gh ta n dw etw e i gh to ft h e
scaﬀolds are 3.5mg and 45.0mg, respectively, with an aver-
age wet tear strength of 0.48 ± 0.0131lb/mm. The collagen
composite scaﬀolds, derived from bovine hide, resemble the
structure of collagen within the extracellular matrix, and are
able to support both short- and long-term diﬀerentiation of
multiple cell types. The 3D scaﬀolds were individually placed
into separate wells of a 48-well plate, and were immersed in
asolutionconsistingof200μLofculturemediumcontaining
approximately 50,000 LacZ+ myoblasts. The scaﬀolds were
then incubated in 37◦Ca t5 %C O 2 for 1 hour.
2.3. Rolling Bottle Cell Culture System. The LacZ+ myoblast
seeded scaﬀolds were transferred from the 48-well plates into
Corning cell culture bottles containing 200mL of culture
media. The Corning cell culture bottles were placed on a
Wheaton rolling device (Fischer Scientiﬁc) at a speed of 5
revolutions per minute (RPM). The Wheaton rolling device
was then placed in an incubator at 37◦C and 5% CO2 for 3
weeks with periodic cell culture media changes.
2.4. Scaﬀold Sectioning and Immunostaining. In vitro, the
scaﬀolds were harvested after 1, 2, and 3 weeks of culturing,
and rinsed with PBS before being snap-frozen in 2-methyl
butane precooled in liquid nitrogen and stored at −80◦C.
The scaﬀolds were then cryosectioned at 10μma n dp r e p a r ed
for immunostaining.
In vivo,s c a ﬀolds were harvested at various time points,
and immunostaining was performed to detect CD31, vWF,
dystrophin, neuroﬁlament protein, and fast MyHC expres-
sion in injured GMs implanted with the myoblast seeded
scaﬀolds. Tissue sections were ﬁxed in 4% formalin for 5
minutes followed by washing with PBS. Nonspeciﬁc binding
was blocked with 10% HS for 1 hour at room temperature
(RT). Primary antibodies were diluted to 1:200 in 2% HS
and incubated overnight at 4◦C. The sections were then
rinsed with PBS followed by secondary antibody incubation
for 1 hour at RT in a 1:300 dilution. The sections were then
rinsed with PBS before the nuclei were counterstained with
DAPI.
2.5. Proliferation Assay. After 10 days of culturing the
scaﬀolds in the Wheaton rolling device, a BrdU assay was
performed in order to evaluate the proliferation capacity of
the C2C12 myoblasts within the scaﬀold. BrdU was added
to growth medium at dilution of 1:1000 for an incubation
period of 24 hours. The scaﬀolds were then removed from
themediumandrinsedwithPBSbeforebeingsnap-frozenin
2-methyl butane precooled in liquid nitrogen. The scaﬀolds
were then sectioned and ﬁxed with 4% formalin. The DNA
was denatured for 10min on ice with 1N HCl followed by
2N HCl at RT for 10min, and ﬁnally 2N HCl for 20min at
37◦C. Nonspeciﬁc binding was blocked with 10% HS for 1
hour. The primary antibody (biotin conjugated anti-BrdU)
was added at a 1:250 dilution in 2% HS for 3 hours at RT.
Thesecondaryantibody(biotinstreptavidin)wasthenadded
at a dilution of 1:400 for 1 hour at RT. The nuclei were then
counterstained with DAPI.
2.6. Animal Experiments. The animal protocol was approved
by the Animal Research and Care Committee at Children’s
Hospital of Pittsburgh. The mice included normal (C57BL6J,
5–8 weeks of age, male), SCID (C57BL/6J-Prkdcscid/SzJ, 4–
8 weeks of age, female), and dystrophic/immunodeﬁcientJournal of Biomedicine and Biotechnology 3
mdx/SCID (C57BL/10ScSn-Dmdmdx crossed with C57BL/6J-
Prkdcscid/SzJ, 4–8 weeks of age, female). All mice were
purchased from Jackson Laboratory (Bar Harbor, Maine),
and were housed individually with proper access to food and
water and maintained on a 12-hour light/dark cycle. After
the mice were anesthetized, an approximately 4 ×4 ×3mm 3
defect was created in the belly of the gastrocnemius muscle
(GM). The 3D muscle grafts and control nonseeded scaﬀolds
were implanted in the defects followed by immediate wound
closure. At designed time periods, mice were sacriﬁced, and
the GMs were harvested and snap-frozen in 2-methylbutane
precooledinliquidnitrogen,andtheywerecryosectionedfor
histological analysis.
3. Results
3.1. In Vitro. In the in vitro portion of the experiments, the
C2C12 myoblast seeded scaﬀolds were cultured in a roller
bottle cell culture system, and the scaﬀolds were harvested
after 1, 2, and 3 weeks of culturing. After 1 week of culture,
myoblasts were distributed throughout the interior of the
scaﬀold which provides evidence that extensive migration
was able to occur (Figures 1(a)–1(f)). Some of the cells
migrated into the interior region of the scaﬀold, and this
c a nb ed e t e c t e db ye i t h e rH E( F i g u r e s1(a)–1(c)) or LacZ
(Figures 1(d)–1(f)) staining. The sectioned scaﬀolds were
also immunostained for CD31, an endothelial marker, and
vWF, an endothelial cell-speciﬁc protein (Figures 2(a)–2(c)).
After 1 week of culture, CD31positive cells were seen within
thescaﬀold(red,Figure 2(a)).ColocalizationbetweenCD31-
positive (red) and vWF-positive (green) cells was visualized
after2weeksofculture(yellow,Figure 2(b)).Thedetectionof
the colocalization of CD31 positive and vWF positive cells is
indicative of vascular development within the scaﬀold. After
3weeksofculturing,moreextensivecolocalizedpositivecells
were seen (yellow, Figure 2(c)). A BrdU assay was performed
in order to assess the viability and proliferative capacity of
the myoblasts within the scaﬀold. We detected myoblasts
with nuclei positive for BrdU (red, Figures 2(d), 2(e),a n d
2(f)), revealing that some of the myoblasts seeded within the
scaﬀo l dw e r ea b l et op r o l i f e r a t e .
3.2. In Vivo. In the normal mouse model, implantation of
a nonseeded control scaﬀold resulted in rejection from the
host tissue, and this was seen 20 days after implantation
(Figure 3(a)). In the SCID mouse model, the implanted
nonseeded scaﬀolds were not rejected by the host tissue, but
few host cells migrated into the area of the implantation
(Figure 3(b)). In the same SCID mouse model, implantation
of the 3D muscle graft with LacZ-positive myoblasts for a
durationof20days,resultedindetectionoflargepopulations
of LacZ-positive cells remaining in the transplantation site as
well as extensive migration of the LacZ-positive cells into the
surrounding host tissue, which demonstrates the success of
the 3D graft implantation into the host tissue (Figure 3(c)).
With immunostaining, we discovered CD31 and vWF posi-
tive cells present within the interior of the scaﬀold, and some
of these cells expressed colocalization of the two markers
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Figure 1: Cell growth examined after 1 week of culturing in
vitro. Cells were visualized throughout the scaﬀold with a higher
concentration of cells located on the periphery of the scaﬀolds;
however, extensive migration is seen within the scaﬀolds. H&E
stainingofthescaﬀolds((a)–(c)),andLacZandeosinstaining((d)–
(f)) are shown.
(Figure 3(d)), indicating that the vasculature process had
began to develop.
In the mdx/SCID mouse model, we followed the same
p r o c e d u r ed e s c r i b e da b o v ef o rt h en o r m a lm o u s em o d e l .
We observed that the trauma sites were quickly healed in
the 3D muscle graft implanted skeletal muscle after 10
(Figure 4(a)) and 20 days (Figure 4(c)) after surgery in
comparison to the healing seen in the nonseeded scaﬀolds
implanted into the muscle (Figures 4(b) and 4(d)). By
histological analysis, the LacZ-positive cells were able to
survive within the implanted scaﬀo l da sw e l la sm i g r a t e
throughout the scaﬀold. The scaﬀold began to breakdown
as it was incorporated within the surrounding host tissue 10
days after implantation (Figures 4(e) and 4(f)). Twenty days
after the graft implantation, we also detected that multiple
cell types were spread homogeneously throughout the site
of injury, and signiﬁcantly, we detected CD31 and vWF
positive cells present in the new tissue and some of these
cells demonstrated colocalization between these two markers
(Figures 4(g) and 4(h)). This result indicates that the
vascularization process had started within the 3D muscle
graft as early as 10 days after implantation.
We also investigated the histology of the long-term 3D
muscle graft after implantation in the mdx/SCID mouse
model. One month after implantation of the 3D muscle
graft, LacZ and eosin staining provided evidence that the
LacZ-positive myoblasts were able to survive within the
implanted scaﬀold (Figure 5(a)). The site of injury was
composed of LacZ-positive myoblasts and nondegraded
residues of the scaﬀold (Figure 5(a) and 5(c) arrows).
Some LacZ-positive myoblasts were detected at the periph-
ery of the scaﬀold forming LacZ positive multinucleated
myotubes (Figure 5(a), arrowheads). Many desmin positive
cells (arrowheads), indicative of mature muscle cells, were
detected within the area of implantation around nonde-
graded regions of the scaﬀold (Figure 5(b), arrows). With
an H&E staining, we detected newly formed myoﬁbers
within the region of the degrading scaﬀold (Figure 5(d)).4 Journal of Biomedicine and Biotechnology
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Figure 2: Immunoﬂuorescent staining of the scaﬀolds after culturing for 1, 2, and 3 weeks in vitro for evidence of vasculature ((a)–(c)).
After one week of culturing (a), CD31 positive cells (red) are detected within the scaﬀold. After two weeks of culturing (b), colocalization
of CD31 (red)a n dv W F( green) positive cells are visualized. After three weeks of culturing (c), more extensive colocalization of CD31 and
vWF is seen. A BrdU assay was performed in vitro after 10 days of culturing ((d)–(f)). BrdU positive nuclei (red) were seen revealing that
proliferation was occurring throughout the scaﬀold (e).
x100 x200
LacZ-blue
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Figure 3:TheimmunocompatibilityofthescaﬀoldswasexaminedinnormalmiceandSCIDmice invivo.Twentydaysafterimplantationin
thenormalmousemodel, nonseeded scaﬀolds were rejected bythe hosttissue(a).Twenty days after implantationintheSCIDmousemodel,
nonseeded scaﬀolds were not rejected by the host tissue, and few host cells migrated into the scaﬀold (b). Twenty days after implantation in
the SCID mouse model, LacZ-labeled C2C12 myoblast seeded scaﬀolds were well received in the host tissue (c). Also, LacZ+ cells were able to
migrate into the surrounding host tissue. An immunoﬂuorescent staining of CD31 (red)a n dv W F( green) was performed on the implanted
seeded scaﬀo l d s2 0d a y sa f t e ri m p l a n t a t i o n( d ) .
With immunostaining, dystrophin-positive myoﬁbers were
detected within the implantation region which suggests
that regeneration was occurring within the site of injury
(Figure 5(e), arrowheads). We also discovered that some
CD31 positive cells were located within the site of injury,
revealing that the vascularization was an ongoing process
(Figures 5(e) and 5(f), arrows).
Two months after implantation of the 3D muscle grafts,
large dystrophin positive grafts were detected within the
site of injury suggesting that muscle regeneration had takenJournal of Biomedicine and Biotechnology 5
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Figure 4: In the mdx/SCID mouse model, healthy healing was observed in the myoblast seeded scaﬀolds after 10 days (a) and 20 days
(c). Nonseeded scaﬀolds implanted into mdx/SCID mice resulted in slower and less healthy healing at 10 days (b) and 20 days (d). LacZ
staining of the implanted muscle graft region revealed extensive migration of the LacZ+ myoblasts into the surrounding host tissue (e) and
(f). Immunoﬂuorescent staining of CD31 (red)a n dv W F( green) showed vascularization developing in the implanted muscle graft region
20 days after implantation (g). A DAPI staining revealed that a variety of cell types were located homogenously throughout the implanted
muscle graft area (h).
(a) (b) (c)
(d) (e) (f)
Figure 5: LacZ and eosin staining 1 month after implantation revealed that numerous LacZ+ myoblasts were able to survive within the
implanted muscle graft region ((a) and (c)). Residues of nondegraded scaﬀold were also visualized within the implanted muscle graft area
((c), arrowheads). LacZ+ myoblasts were seen forming multinucleated myotubes within the implanted area ((a) arrows). Desmin positive
myoblasts ((b)arrowheads) were detected within the vicinity of nondegraded portions of the scaﬀold ((b) arrows).An H&E staining revealed
newly formed myoﬁbers within the implantation site (d). Dystrophin-positive myoﬁbers (red, arrowheads) were detected 1 month after
implantation (e) as well as CD31-positive cells, ((e) and (f), green).
place in many regions of the injured area (Figures 6(a) B,
E, and H). Also, the majority of the dystrophin-positive
grafts stained positive for fast myosin-heavy chain protein
(Figures 6(a) G–I). Similar to the previous time points,
CD31 was visualized which provides evidence for extensive
vascular development within the site of injury (Figures 6(a)
A–C). Also neuroﬁlament protein was detected within the
dystrophin-positive grafts suggesting that innervations were
being formed to the regenerating myoﬁbers (Figure 6(a)
D–F). With histological analysis, we have detected a large
area of scar tissue remaining in the implanted 3D graft
sites three months after implantation through an H&E
staining (Figure 6(b) Aa n dB ,stars) .A l s o ,w eh a v ed e t e c t e d
regeneration ofmyoﬁbers (Figure 6(b) B,a r r o w s ) and large
amounts of dystrophin-positive myoﬁbers within the new
muscle graft (Figure 6(b) Ca n dD ,d y s t r o p h i n - r e d ,a r r o w s )
with revascularization (Figure 6(b) D, CD31-green, arrow-
heads). This existing scar tissue may be a major factor to6 Journal of Biomedicine and Biotechnology
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Figure 6:(a)Threemonthsafterimplantationinvivo,largedystrophin-positivegraftswerevisualized((a)B,E,H).CD31-positivecellswere
detected within the dystrophin-positive grafts indicative that vascularization and regeneration were occurring ((a) A–C). Neuroﬁlament
protein was visualized within the dystrophin-positive grafts revealing that innervations were forming along with the regenerating myoﬁbers
((a) D–F). The majority of the dystrophin-positive grafts stained positively for fast myosin-heavy chain protein ((a) G–I). (b) Three
months after implantation in vivo, all newly formed myoﬁbers stained positive for dystrophin ((b) A dystrophin-red). A small quantity
of the dystrophin-positive myoﬁbers stained positive for slow myosin-heavy chain protein ((b) B slow MyHC-gray). A larger quantity of the
dystrophin-positive myoﬁbers stained positive for fast myosin-heavy chain protein ((b) C fast MyHC-green). (b) D displays a merged image
revealing the distribution of the two types of myosin-heavy chain proteins.Journal of Biomedicine and Biotechnology 7
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Figure 7: Three months after implantation, evaluation of the
regenerative capacity of the seeded scaﬀolds. A hematoxylin and
eosin staining revealed a large area of ﬁbrosis in the muscle graft
((a) and (b),s k ). However, within the muscle graft despite the
area of ﬁbrosis, we detected regenerating myoﬁbers ((b), arrows f),
and large quantities of dystrophin-positive myoﬁbers ((c), arrows
f). Within the areas of regeneration, revascularization was detected
through the visualization of CD31-positive cells ((d) green/arrows
f).
interfere with further muscle functional recovery, and can
be a potential inducer of muscle reinjury with movement.
Thus, prevention of ﬁbrosis is necessary for the success of the
bioengineered tissue in application.
4. Discussion
In the last few decades, advances in bioengineering have
moved the ﬁeld of tissue engineering signiﬁcantly forward
[15, 23, 24]. While 3D tissue constructs are still being
developed, this ﬁeld continues to grow from the intense
eﬀorts of military and civilian trauma researchers. Tissue
engineering techniques combined with cell biology and
material sciences hold great promise in developing appro-
priate strategies for the repair and regeneration of biological
tissues. The necessary components for successful 3D engi-
neered tissues have been identiﬁed to include the following:
a biodegradable material that serves as a scaﬀold to facilitate
new tissue growth, and pluripotent or stem cells to initiate
new tissue growth as well as promoting vascularization and
innervation once implanted within the patient. Our work
focusedprimarilyoncreatingfunctional3Dtissueconstructs
in vitro, through the use of a 3D biodegradable scaﬀold
seeded with C2C12 primary myoblasts, which could then be
implanted in vivo for the purpose of repairing and replacing
damaged and lost tissue due to soft tissue defects.
Our results conﬁrmed that C2C12 myoblasts are able
to survive and migrate within the 3D collagen composite
scaﬀold in vitro. This is a necessary step to occur prior to
implantation in order to ensure that the implanted scaﬀolds
are incorporating a rich source of myoblasts into the area of
the skeletal muscle injury. Also, we discovered that in vitro,
CD31-positive cells were present after 1 week of culturing.
CD31 is an endothelial marker that signiﬁes progenitor
blood vessel cells [25, 26] which means that the cell seeded
scaﬀold had already started to develop some form of vascu-
lature prior to implantation. This is furthered by evidence
thatafter2weeksofculturinginvitro,colocalizationbetween
CD31- and vWF-positive cells was detected. These results
indicatethatthecellseededscaﬀoldsarecapableofforminga
type of prevascularization which is ideal for inducing vascu-
lar development within the defected muscle once implanted.
The ability to promote vascularization is an essential
aspectoftissueengineering becauseoftenthevascularization
to the area where the tissue loss took place is compromised
by the trauma itself [4]. The vascularization that was seen
in vitro was also present when the scaﬀolds were harvested
at various time points after implantation in vivo.T h e
detection of CD31-positive cells located throughout the
scaﬀold provide evidence that vascularization was being
incorporated within the scaﬀold from vessels located in the
host tissue surrounding the defect. This incorporation of
vasculature within the scaﬀold increased the cell survival of
themyoblastsbyprovidingnutrientsandoxygentothenewly
transplanted cells [27, 28]. In order for a tissue construct to
be eﬀective in becoming functional, vascularization needs
to occur along with innervation. Techniques for repairing
soft tissue defects, such as muscle and perforator ﬂaps, result
in providing vascularized coverage to the wound; however,
due to the lack of innervations to the damaged area, sen
sitivity is often compromised [6]. Our results indicated that
the seeded scaﬀold was successful in providing potential
innervations to the damaged tissue based on the presence
of neuroﬁlament-positive cells. Neuroﬁlament protein is a
protein located in the intermediate ﬁlament of neurons [29];
therefore, its expression is indicative of neurogenesis and
neural development.
Dystrophin-positive myoﬁbers were found located
within the area of the defect which signiﬁes that new muscle
ﬁberswerebeingformedinthedamagedarea.Themyoblasts
that were seeded in the scaﬀo l dw e r ea b l et os u c c e s s f u l l y
diﬀerentiate into myotubes which allowed for regeneration
of the damaged tissue. This result is not surprising due to
numerous previous studies that found that myoblast trans-
plantation is an eﬀective therapy for increasing dystrophin-
positive myoﬁbers in such muscle dystrophy diseases such
as Duchenne muscular dystrophy [30–32]. A large quantity
of the dystrophin-positive myoﬁbers stained positively for
fast-type myosin-heavy chain protein, and a lower quantity
stainingpositivelyforslow-typemyosin-heavychainprotein.
This preferential diﬀerence may be contributed to the
environment into which the myoblasts were implanted [33].
Ifmorefast-typemyosin-heavychainmyoﬁberswerepresent
in the surrounding area of host tissue around the defect, dif-
ferentiation of the myoblasts into myotubes exhibiting fast-
type myosin-heavy chain proteins may have been favored.
Although many challenges still remain in the successful
restorationofsofttissuedefects,ourstudyprovidesastarting
point for overcoming these challenges. The ability of the
myoblast seeded collagen composite scaﬀolds to provide the
initial architecture for rebuilding a functional tissue, as well
asincorporatinganappropriatepopulationofcellsthathelps8 Journal of Biomedicine and Biotechnology
to facilitate muscular regeneration through increasing inner-
vation, vascularization, and the production of myoﬁbers,
makes the 3D collagen scaﬀold an ideal candidate for
repairing soft tissue defects. However, immunocompatibility
and ﬁbrosis are two problems that still remain. As seen
in our data, only immune-compromised mice were able
to successfully integrate the 3D tissue graft into their host
tissue which presents a limited scope of application for the
scaﬀolds. Also, ﬁbrosis is a pathological process that aﬀects
many tissues and organs after being aﬄicted by injuries or
disease-likestates[34].Thedevelopmentoftheﬁbrotictissue
can lead to chronic healing problems, which can result in
tissue/organ dysfunction during the ﬁnal healing stages, and
can make the tissue more susceptible to reinjury after initial
healing [35, 36]. Our study detected ﬁbrosis formation in the
skeletalmusclesafterlong-termimplantation,indicatingthat
prevention or treatment of the ﬁbrous scar tissue is essential
for eﬀective bioengineered tissues.
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